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OBJECTIVE — To evaluate an algorithm guiding responses of continuous subcutaneous
insulininfusion(CSII)–treatedtype1diabeticpatientsusingreal-timecontinuousglucosemon-
itoring (RT-CGM).
RESEARCH DESIGN AND METHODS — Sixty CSII-treated type 1 diabetic partici-
pants (aged 13–70 years, including adult and adolescent subgroups, with A1C 9.5%) were
randomized in age-, sex-, and A1C-matched pairs. Phase 1 was an open 16-week multicenter
randomized controlled trial. Group A was treated with CSII/RT-CGM with the algorithm, and
group B was treated with CSII/RT-CGM without the algorithm. The primary outcome was the
difference in time in target (4–10 mmol/l) glucose range on 6-day masked CGM. Secondary
outcomes were differences in A1C, low (3.9 mmol/l) glucose CGM time, and glycemic vari-
ability. Phase 2 was the week 16–32 follow-up. Group A was returned to usual care, and group
B was provided with the algorithm. Glycemia parameters were as above. Comparisons were
made between baseline and 16 weeks and 32 weeks.
RESULTS — In phase 1, after withdrawals 29 of 30 subjects were left in group A and 28 of 30
subjects were left in group B. The change in target glucose time did not differ between groups.
A1C fell (mean 7.9% [95% CI 7.7–8.2to 7.6% [7.2–8.0]; P  0.03) in group A but not in group
B (7.8% [7.5–8.1] to 7.7 [7.3–8.0]; NS) with no difference between groups. More subjects in
group A achieved A1C 7% than those in group B (2 of 29 to 14 of 29 vs. 4 of 28 to 7 of 28; P 
0.015). In phase 2, one participant was lost from each group. In group A, A1C returned to
baseline with RT-CGM discontinuation but did not change in group B, who continued RT-CGM
with addition of the algorithm.
CONCLUSIONS — Early but not late al-
gorithm provision to type 1 diabetic patients
usingCSII/RT-CGMdidnotincreasethetarget
glucose time but increased achievement of
A1C 7%. Upon RT-CGM cessation, A1C re-
turned to baseline.
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R
eal time-continuous glucose moni-
toring (RT-CGM) can be integrated
withacontinuoussubcutaneousin-
sulin infusion (CSII) device (1,2). Inter-
stitial glucose readings, with direction
and rate of change, are displayed and
linked to low and high glucose alarms.
Data can be uploaded and reviewed ret-
rospectively. Apart from recent devices
with automatic shutoff for low glucose,
RT-CGM cannot initiate insulin delivery.
Insulin changes must be initiated by the
patient or caregiver. Continuous glucose
monitoring (CGM) data interpretation
can be difﬁcult, and advice guiding insu-
lin or lifestyle change may enhance bene-
ﬁts (3).
In this study, we tested the glycemia
effects of an algorithm guiding responses
to RT-CGM in CSII-using type 1 diabetic
subjects. We also evaluated whether glu-
cose changes persisted after RT-CGM
withdrawal and whether late algorithm
introduction improved glycemia.
RESEARCH DESIGN AND
METHODS— Thestudywasanethics
committee–approved randomized con-
trolled trial at three adult and two pediat-
ric Australian centers. Written informed
consentwasobtained,includingguardian
consent for pediatric participants.
Participants were recruited in pairs
matched for age (within 5 years), sex, and
A1C (within 1%). Inclusion criteria were
age 13 years, type 1 diabetes duration
1 year, 3 months CSII with bolus cal-
culator use, A1C 9.5%, self-monitoring
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access, and willingness to use RT-CGM
for6ofeach7daysforthestudyduration.
Exclusion criteria were physical or intel-
lectual limitations, renal impairment (es-
timatedglomerularﬁltrationrate60ml/
min), using or likely to require steroid
therapy,gastroparesis,untreatedceliacor
thyroid disease, hemoglobinopathies,
regular blood transfusions, current or
planned pregnancy, and breast-feeding.
No data were available regarding gly-
cemia after RT-CGM initiation at time of
study design. The only CGM data avail-
able were retrospective continuous glu-
cose monitoring system (Medtronic,
Northridge, CA) traces recorded within 3
months after CSII commencement (with-
out RT-CGM) in 40 patients at one adult
center, which demonstrated a 33% in-
creasein4–10mmol/ltimeto58%(17%)
and mean  SD A1C reduction from
7.9  1.4 to 7.1  1.0%. A between-
group difference in the target glycemia
timeincrementof25%waschosenforthe
studybecausetheimpactofRT-CGMand
thealgorithmwasexpectedtobelessthan
that of CSII initiation. Thirty participants
in each (algorithm and nonalgorithm)
group had 99% power to detect a 25%
differencebetweengroupsatthe0.05sig-
niﬁcance level. Corresponding power for
18 adults and 12 adolescents per group
was 95 and 90%, respectively.
Protocol
A history was obtained, physical exami-
nation was performed, and blood and
urine were collected. BMI SD score was
calculated for adolescents (4). All partici-
pantswereprovidedwithandeducatedin
operation of the MiniMed MMT 722 Par-
adigm Real-Time system and web-based
CareLink software (Medtronic) for glu-
cose and pump parameter review (1,2). A
prerandomization 6-day masked CGM
device (Guardian System; Medtronic)
was worn without wearer access to real-
timeglucoseinformation,anddatawere
uploaded by users. Real-time sensor
function was not activated until ran-
domization.
Phase 1
Participant pairs were computer-
randomized centrally to receive the algo-
rithm (group A) or no further RT-CGM
interpretation guidelines (group B) for 16
weeks. All participants were requested to
wearthesensor,whichwastobechanged
every 3 days, for 6 of 7 days. All were
instructed to upload to Carelink, review
their RT-CGM data every 1–2 weeks, and
alter their insulin delivery accordingly.
One week before the end of phase 1, the
6-day masked CGM device was worn
along with the unmasked Paradigm de-
vice, with both linked to a single
transmitter.
Phase 2
Group A participants returned to usual
care (CSII without RT-CGM) and were
followed for a further 16 weeks. Group B
participants continued CSII/RT-CGM,
were provided the algorithm, and were
followed for 16 weeks. One week before
the end of phase 2, the 6-day masked
CGM device was again worn.
All participants received routine care
from their own health professionals with
no additional clinician visits. A safety-
monitoring team, not involved in partici-
pant care, accessed uploaded CGM data,
which were only made available to care
providers if the individual was judged to
be at risk of severe hypoglycemia or
ketoacidosis.
Algorithm
A two-part (reactive and proactive) algo-
rithm advising responses to RT-CGM was
devisedbyphysiciansandcertiﬁeddiabe-
tes nurse educators (DNEs) with input
from CSII-using (nonstudy participant)
patients. (Supporting information is
found in supplementary Appendix A,
available at http://care.diabetesjournals.
org/cgi/content/full/dc09-1481/DC1. This
includes the wallet card [reactive algorithm],
wall chart [proactive algorithm], and
teaching manual.) The algorithm was to
guideimmediateresponsestoglucoselev-
els and trends, as well as proactive
changes to pump basal insulin settings,
insulin to carbohydrate ratios, and cor-
rection factors. Participants assigned to
receivethealgorithminphase1(groupA)
received education, averaging 90 min,
either on a one-to-one basis or in pairs.
They were provided with paper and
electronic versions of the algorithm, a
wallet card summarizing reactive guide-
lines, and a wall chart summarizing
proactive changes to assist RT-CGM up-
load review (available at http://www.
diabetesccre.unimelb.edu.au). In response
to phase 1 (group A) comments, phase 2
(group B) participants were also given a
handset summarizing the reactive algo-
rithm. After entering the glucose level,
number and direction of arrows, and time
since food and relation to bedtime, the sug-
gested algorithm response would appear
on-screen.Theparticipantenteredwhether
he or she agreed or disagreed. Handset in-
teractions were automatically transmitted
to a remote database. Site uniformity was
ensured by a prestudy group meeting of
DNEs to review the education document
and the lead site DNE observing each
site’s algorithm teaching.
Glycemia
Six-daymaskedCGMdataatbaselineand
study end were used to quantify percent
time in target (4.0–10.0 mmol/l), low
(3.9mmol/l),andhigh(10.1mmol/l)
glucose ranges. Glycemic variability was
estimated by mean amplitude glycemic
excursion (MAGE) (5). A1C (baseline, 16
weeks, and 32 weeks) was quantiﬁed by
an independent Diabetes Control and
Complications Trial–accredited laboratory
(Primus CLC330 afﬁnity high-pressure liq-
uid chromatography analyzer). Phase 1
primary outcome was the difference be-
tween algorithm and nonalgorithm
groups in target glucose time. Second-
ary outcomes were differences in A1C,
time in low and high glucose ranges,
and MAGE derived from CGM traces.
Phase 2 outcomes were glycemia as
above, comparing 32 weeks with 16
weeks and baseline.
Statistics
SAS (version 9.1.3; SAS Institute, Cary,
NC) was used. For continuous data (per-
cent target, high and low glucose time,
A1C, and MAGE), two-way repeated-
measures ANOVA was used. Models in-
cluded tests of time, algorithm use, and
theinteractiontermfortimebyalgorithm
use. Count data (percentage with A1C
7%) used Fisher’s exact test for be-
tween-groupcomparisonsandtheMcNe-
mar test for paired proportions.
Correlations are Spearman correlations.
Signiﬁcance was taken at P  0.05.
RESULTS— Of 60 recruits (from 68
patients approached), 57 (95%) returned
for the phase 1 end visit, with withdraw-
als as noted in Fig. 1. Fifty-six com-
menced phase 2 as 1 (group B) adult
discontinued because of severe skin reac-
tionstoadhesives.OnegroupAadultwas
lost to follow-up (Fig. 1). Masked 32-
week CGM data were unavailable for four
(three group A and one group B) partici-
pants (two declined to wear the device,
one device failed to record, and one de-
vice failed to upload). Baseline character-
istics are shown in Table 1.
Jenkins and Associates
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Mean  SD sensor use in phase 1 was
4.5  1.3 days/week and did not differ
between subjects provided versus not
provided the algorithm (4.7  1.0 vs.
4.41.5days).Sensorusewasgreaterin
adults than in adolescents (4.8  1.3 vs.
4.1  1.0 days; P  0.02). Sensor use by
group B in phase 2 (4.3  1.5 days) did
not differ from that in phase 1.
Glycemia
Phase 1. There were no statistically sig-
niﬁcant differences in target glucose time
changes in group A or B nor any differ-
ence by algorithm assignment. A1C de-
creased in group A (P  0.03) but not in
group B (Fig. 2A). A1C change did not
vary signiﬁcantly by algorithm assign-
ment. More participants in group A than
in group B achieved A1C 7.0% (P 
0.015). In both groups, MAGE and low
glucose time did not change signiﬁcantly
(Table 2).
A1C for group A adults decreased
(P  0.001). The difference between
groups A and B approached signiﬁcance
(P0.08)(Fig.2B).MoregroupAadults
achieved A1C 7.0% (2 of 18 at baseline
and 13 of 18 at 16 weeks) than group B
adults (4 of 17 at baseline and 6 of 17 at
16 weeks; P  0.0045). A1C did not
change in adolescents (Fig. 1C) nor vary
by algorithm assignment. A1C change
differed between algorithm-assigned
adults and adolescents by 0.77% (0.62 
0.43% reduction in adults vs. 0.15 
0.99% increase in adolescents; P 
0.032).
The association of A1C (16 weeks)
with sensor use time, age-group, and
(time using sensor  age-group) interac-
Figure 1—Flow of participants through the study.
Table 1—Baseline clinical characteristics of adult and adolescent CSII-RT-CGM users randomized to group A or group B who returned for the
16-week visit
All subjects Adult subjects Adolescent subjects
Group A Group B Group A Group B Group A Group B
Subjects (male/female) 11/18 11/17 6/12 6/11 5/6 5/6
Age (years) 30.3  14.8 29.7  14.0 37.7  12.0 39.1  12.5 16.7  1.2 16.7  1.6
Diabetes duration (years) 14.6  10.1 15.4  10.4 18.7  10.0 18.7  11.4 7.8  5.5 10.1  6.4
CSII (years) 2.6  1.7 2.5  1.6 2.6  1.9 2.7  1.8 2.4  1.6 2.3  1.1
Total insulin (units/kg/day) 0.68  0.15 0.74  0.29 0.64  0.12 0.62  0.24 0.76  0.16 0.93  0.27
BMI (kg/m
2) NA NA 27.5  3.1 28.5  7.0 1.71  0.45 1.26  0.75
Macrovascular disease 0/29 2/28 0/18 2/17 0/11 0/11
Neuropathy 2/29 1/28 1/18 1/17 1/11 0/11
Retinopathy 1/29 2/28 1/18 2/17 0/11 0/11
Nephropathy 2/29 0/28 1/18 0/17 1/11 0/11
Data are expressed as n or means  SD. Adolescent subjects results are expressed as BMI SD scores (4). NA, not applicable.
A RT-CGM CSII algorithm for type 1 diabetes
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A1C was inversely associated with sensor
use time (B  0.025, P  0.028) and
adulthood (B  2.03, P  0.014). The
inverse association of A1C with sensor
use time was similar in adults and adoles-
cents (P for interaction term  0.248).
The phase 1 mean  SD number of
pump-setting (basal rate and insulin-to-
carbohydrate ratio) changes was greater
in the algorithm group than in the no al-
gorithmgroup(12.711.6vs.6.36.5
changes; P  0.0164) and was similar in
adults and adolescents (11.3  11.3 vs.
7.1  6.8; P  0.14). A trend was ob-
served between the number of pump-
setting changes and (16 weeks) A1C in
algorithm users (r  0.35; P  0.07)
but not in those without the algorithm
(r  0.08; P  0.7).
Phase 2. In group A, A1C at 32 weeks
washigherthanthatat16weeksandsim-
ilar to baseline (Fig. 2A) for the whole
group,drivenbytheadults(Fig.2B).A1C
in adolescents did not change signiﬁ-
cantly(Fig.2C).Therewerenosigniﬁcant
changes in target or low glucose time or
MAGE.
In group B, there were no signiﬁcant
changes in target or low glucose times,
A1C, or MAGE at 32 weeks versus base-
line or 16 weeks. Handset use was greater
in adults versus adolescents (mean 118
[range 0–434] vs. 50 [0–260] interac-
tions; P  0.05). Users disagreed with al-
gorithm-handset advice on 1.6  2.3%
interactions, being similar in adults and
adolescents (1.7  2.4 vs. 1.5  2.2%;
P  0.5). The number of handset interac-
tions correlated with percent target range
time (r  0.4; P  0.04) and A1C at 32
weeks (r  0.5; P  0.009) and change
in A1C between 16 and 32 weeks (r 
0.4;P0.04).Morethan80%ofhand-
set interactions occurred within the ﬁrst
month (Fig. 2D).
Adverse events
One phase 1 group B female adolescent
developed depression and an eating dis-
order.OnegroupAmaleadulthadsevere
skin reactions to sensor adhesives. An-
other group A male adult experienced a
sensor insertion site infection requiring
outpatient antibiotics. One male adoles-
cent and one female adult, both group A,
experiencedtwoseverehypoglycemicep-
isodes in phase 1, attributable to guide-
line breaches (sensor alarms turned
down, inappropriate sensor calibration,
bolus administration without bolus cal-
culator use, and deliberate entry of inac-
curate data into the bolus calculator). In
phase 2 one group A female adult experi-
enced a severe hypoglycemic episode.
Four participants had pump malfunc-
tions requiring replacement.
CONCLUSIONS — CSII-experienced
type 1 diabetic patients commencing RT-
CGM provided a decision support algo-
rithm (group A) did not change target
glucose time, the primary study end
point, but their A1C fell signiﬁcantly.
There was no change in those without the
algorithm (group B) and between-group
differences were not signiﬁcant. A signif-
icantly greater proportion of patients in
group A achieved A1C 7.0%, without
increased low glucose time.
In the present study, MAGE at base-
line was in the range consistent with type
1 diabetes (5,6) and did not improve sig-
niﬁcantlywithRT-CGMusewithorwith-
out the algorithm. This lack of beneﬁt, in
keepingwithpreviousobservations(6,7),
may represent limitations of both the al-
gorithm itself and the tools used to mea-
sure glycemic variability.
Nostudies(6–12)haveexaminedthe
glycemia impact of speciﬁc education on
Rt-CGMoutcomes.TheAustralianSensor
Augmented Pump Study (ASAPS) evalu-
ated naive RT-CGM use (6), comparable
to phase 1 group B of this study. In
ASAPS, after 12 weeks, 56% RT-CGM us-
ers achieved A1C 7.0%, with a mean
studyendA1Cof7.1%anda0.2%reduc-
tion.Incomparison,after16weeksofun-
guided sensor use, group B A1C fell by
0.1% to 7.7%, with only 25% achieving
the target. Baseline glycemia of ASAPS
subjects was lower than that in the
present study, suggesting the importance
of patient characteristics.
Table 2—Glycemia variables before and after intervention
Parameter Baseline* 16 weeks 32 weeks
Phase 1 Phase 2
Ptime
(baseline–16
weeks) Pinteraction
Ptime (16–32
weeks)
Ptime
(baseline–32
weeks)
n 57† 55†
Target range (% time)
Group A 55.2 (49.5–60.0) 55.1 (48.2–62.0) 53.4 (46.6–60.3) 0.9062 0.3077 0.4442 0.5864
Group B 61.0 (56.2–65.9) 56.8 (49.4–64.1) 58.9 (53.0–66.8) 0.1235 0.3830 0.6351
A1C (%)
Group A 7.9 (7.7–8.2) 7.6 (7.2–8.0) 8.1 (7.6–8.6) 0.0305 0.3488 0.0196 0.4792
Group B 7.8 (7.5–8.1) 7.7 (7.3–8.0) 7.7 (7.4–8.1) 0.3639 0.5191 0.5918
A1C 7.0%
Group A 2/29 14/29 5/28 0.0005 0.0148 0.0114 0.0833
Group B 4/28 7/28 7/27 0.2568 1.0000 0.1573
Low range (% time)
Group A 4.8 (2.1–7.4) 4.5 (2.3–6.7) 4.1 (2.3–5.9) 0.8787 0.2920 0.5919 0.6298
Group B 4.5 (2.8–6.1) 2.1 (0.86–3.4) 3.3 (1.9–4.7) 0.0301 0.1786 0.0855
MAGE (mg/dl)
Group A 103.3 (93.8–112.8) 100.5 (89.0–112.1) 106.9 (95.3–118.6) 0.6498 0.2651 0.6929 0.4750
Group B 104.1 (92.8–115.4) 92.1 (85.1–99.1) 98.6 (88.4–108.9) 0.0605 0.2986 0.4895
Data are means (95% CI) or n. *Baseline parameters are provided for those participants who returned for the 16 week visit. †Guardian CGM data were available for
56 participants at 16 weeks and 51 participants at 32 weeks.
Jenkins and Associates
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and guidance regarding responses to RT-
CGM were provided, although protocols
were not structured to determine educa-
tion impact. Thus, the relative contribu-
tions of health caregiver guidance versus
that initiated by patients cannot be dis-
cerned. In our study health caregivers
could not access RT-CGM information;
thus, we can examine the beneﬁt of pa-
tient education alone.
Intensive diabetes management with
frequent follow-up has clear beneﬁts
(13,14) but requires substantial staff and
ﬁnancial resources (15). Some RT-CGM
studies followed participants at intervals
of 2–3 weeks (7,9) in person or by tele-
phone (I. Hirsch, MD, University of
Washington, personal communication),
although recent evidence suggests a ben-
eﬁt for RT-CGM in conventional clinical
settings (16). The additional (90 min)
algorithm education in this study is less
burdensomeonthelimitedresourcesthat
characterize many health care systems.
Thetimingofalgorithmprovisionrel-
ative to CSII/RT-CGM commencement
may have an impact on outcome. When
thealgorithmandongoingRT-CGMwere
provided after 16 weeks naive CSII/RT-
CGM use, glycemia was unchanged. Per-
haps during the initial unguided 16
weeks, RT-CGM participants developed
their own responses, which could not
then be modiﬁed by a relatively short
teaching session. In contrast, at baseline
when RT-CGM was novel, participants
would have had no preconceived ideas
and may have more readily used the algo-
rithm provided.
During phase 1 it was not known
whether subjects consulted the algo-
rithm. Indirect evidence supporting the
proactive instruction use may be the
greater number of pump-setting changes
made by the algorithm-provided group.
The handsets incorporated into phase 2
documented consultation of the reactive
algorithm. Despite lack of A1C reduction
after algorithm provision, the number of
handset interactions correlated inversely
with target glucose time, 32-week A1C,
and A1C changes between 16 and 32
weeks. The observed initial intensive
handsetinteraction,whichthendeclined,
mayindicatethatpatientsincorporatethe
reactive changes with time. This is the
ﬁrst time that such technology has been
used to document patient behavior.
By follow-up of (group A) partici-
pants initially allocated the algorithm, we
determined whether RT-CGM beneﬁt
Figure 2—A1C at baseline, 16 weeks, and 32 weeks according to study group in all partici-
pants (A), adult participants (B), and adolescent participants (C) who returned for the
32-week visit. D: Number of interactions with handsets providing “reactive” guidelines on
howtorespondtoreal-timeglucoselevels.*P  0.05,comparedwithbaselineforthe16-week
data and compared with 16 weeks for the 32-week data. **P  0.0001, 16 weeks compared
with baseline.
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weeks after reversion to usual care with
CSII alone, A1C returned to baseline, in-
dicating that ongoing RT-CGM use is re-
quired to maintain A1C improvements.
This ﬁnding supports previous data relat-
ing sensor use time with glycemia (6–9),
although we believe this is the ﬁrst study
to formally examine RT-CGM with-
drawal.
The challenges of glycemic control in
adolescents with type 1 diabetes, includ-
ing those using CSII is recognized (17–
22). Our ﬁndings complement those of
the Juvenile Diabetes Research Founda-
tion (JDRF) study in which 15–24 year
olds assigned RT-CGM had a A1C fall of
only 0.18% from a baseline of 8.0% (7).
In contrast, ASAPS (6) demonstrated an
A1C beneﬁt in adolescents. Baseline gly-
cemia of ASAPS adolescents was better
than that of the JDRF cohort (7) or that in
the present study, and the time for which
the sensor was used was greater in ASAPS
than in this study, both of which may
have inﬂuenced outcome.
Despite the observed A1C beneﬁt,
baseline and 16-week masked CGM data
in algorithm users did not increase target
glucose time. Lack of concordance be-
tween A1C and CGM data is not unique
(6). Subject numbers could limit statisti-
cal power to detect modest differences in
glycemia reﬂected by CGM. Another con-
tributor may be differences between gly-
cemiaassessmentsof6days(CGM)and3
months (A1C). However, analysis of
phase 1 CGM uploads (not shown) re-
garding target glucose time did not sug-
gest an early impact of the algorithm that
was later lost. CGM use may also have
altered subject behavior, with a greater
impact at baseline when it was novel than
at 16 and 32 weeks when it was routine.
Despite more algorithm-assigned
adults reaching target A1C 7%, the
prestated primary end point, target glyce-
mia time, was not met, and the difference
in A1C change between groups did not
achieve statistical signiﬁcance. It may be
that these established CSII-using patients
alreadyhadsufﬁcientdiabetes-relateded-
ucation, with addition of the algorithm
resulting in minor beneﬁt. Inherent bolus
calculator limitations may have also af-
fected outcome. Finally, at algorithm
formulation time, there was limited expe-
rience with RT-CGM data usage. We ac-
knowledge that the algorithm requires
reﬁnement. For example, based on glu-
cose trend arrow information, it did not
suggest increments in premeal insulin
doses above that recommended by the
boluscalculator,norwerechangesinpre-
meal bolus timing suggested.
A remaining question is whether the
adult A1C beneﬁt 16 weeks after RT-
CGM and algorithm provision is main-
tainedoveranextendedtime.Exploration
of glycemia beneﬁt durability is particu-
larly important in light of a DirecNet
Study report of declining sensor use be-
tween 13 and 26 weeks and rising A1C,
despiteinitialimprovement(23).Thereis
a technology-associated burden, indi-
cated by our observation that even with-
out cost barriers most participants chose
not to use real-time sensors 100% of their
availability.Finally,studyparticipantsare
generally well-motivated, and the beneﬁt
we observed in algorithm-assigned adults
maynottranslatetothegeneraladulttype
1 diabetic population.
RT-CGM provides additional infor-
mation regarding glycemia. Data collec-
tion is not an end in itself, rather it is the
enactment on the acquired information
thatisimportant.Analgorithminforming
responses of CSII-using type 1 diabetic
patients to RT-CGM data has been de-
vised and evaluated. Some beneﬁt in
adultshasbeendemonstratedandmaybe
enhanced by algorithm reﬁnement. Ado-
lescent management merits reevaluation.
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